VR Logo

Unrated

Nippon India Pharma Fund - Direct Plan


1 Lakh

Investment Grown to
₹ 2.07 Lakh

₹ 10000

Monthly SIP Grown to
₹ 6.23 Lakh

Suitability:

This is a fund that invests mainly in shares of pharmaceutical and healthcare companies.

We believe that investors should avoid funds that have a narrowly defined investment mandate such as this one. Instead, they should invest in multi-cap funds which provide complete freedom to the fund management team to invest in companies from which it expects maximum gains.

But if you do invest, you must do so only through the SIP route. Click here to read a primer on SIP investing.

Warning: Do not invest in this, or any other pharma sector fund, if you need to redeem your investment in less than seven years.

Taxability of earnings:

Capital gains

  • If the mutual fund units are sold after 1 year from the date of investment, gains upto Rs 1 lakh in a financial year are exempt from tax. Gains over Rs 1 lakh are taxed at the rate of 10%.
  • If the mutual fund units are sold within 1 year from the date of investment, entire amount of gain is taxed at the rate of 15%.
  • No tax is to be paid as long as you continue to hold the units.

Dividends

  • Dividends are added to the income of the investors and taxed according to their respective tax slabs. Further, if an investor's dividend income exceeds Rs. 5,000 in a financial year, the fund house also deducts a TDS of 10% before distributing the dividend.

Read more

ajax-loader
Please wait...

ajax-loader
Please wait...

(₹)
cal
cal

ajax-loader
Please wait...

Trailing Returns (%)

YTD 1-Day 1-W 1-M 3-M 6-M 1-Y 3-Y 5-Y 7-Y 10-Y
Fund 16.37 -0.65 -2.61 2.35 23.56 18.02 55.82 27.53 18.71 19.17 --
S&P BSE Healthcare TRI 14.47 -0.53 -2.74 2.61 21.97 15.57 53.99 20.92 11.47 13.19 --
Equity: Sectoral-Pharma 12.60 -0.44 -2.30 2.16 19.91 13.90 52.88 25.98 14.96 16.84 --
Rank within category 1 10 8 4 1 1 3 1 1 1 --
Number of funds in category 10 10 10 10 10 10 9 4 4 3 0

As on 18-Jun-2021

Peer Comparison

Fund name Rating Launch Date 1-Year Return 3-Year Return 5-Year Return Expense Ratio Assets (Cr)
Nippon India Pharma Fund - Direct Plan
Unrated
Jan-13 55.82 27.53 18.71 0.80 5,238
ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund - Direct Plan  | Invest Now
Unrated
Jul-18 55.10 -- -- 1.19 2,683
SBI Healthcare Opportunities Fund - Direct Plan  | Invest Online
Unrated
Jan-13 55.16 25.31 12.23 1.09 1,899
Mirae Asset Healthcare Fund - Direct Plan  | Invest Online
Unrated
Jul-18 56.31 -- -- 0.55 1,595
DSP Healthcare Fund - Direct Plan  | Invest Online
Unrated
Nov-18 58.91 -- -- 0.74 1,311

Best & Worst Performance

Best Performance Worst Performance
Return (%) Period Return (%) Period
Week 21.40 01-Apr-2020 - 09-Apr-2020 -12.21 05-Mar-2020 - 12-Mar-2020
Month 38.63 23-Mar-2020 - 22-Apr-2020 -21.01 20-Feb-2020 - 23-Mar-2020
Quarter 47.66 23-Mar-2020 - 22-Jun-2020 -14.04 29-Dec-2015 - 29-Mar-2016
Year 90.70 23-Mar-2020 - 23-Mar-2021 -15.12 08-Sep-2016 - 08-Sep-2017

Risk Measures (%)

Mean Std Dev Sharpe Sortino Beta Alpha
Fund 28.83 20.63 1.19 2.69 0.87 6.87
S&P BSE Healthcare TRI 24.50 23.02 0.88 1.97 -- --
Equity: Sectoral-Pharma 27.27 20.37 1.13 2.49 0.86 5.57
Rank within category 1 2 2 2 3 1
Number of funds in category 4 4 4 4 4 4

The Risk Measures have been calculated using calendar month returns for the last three years.

As on 31-May-2021

Asset Allocation (%)

ajax-loader
Please wait...

Concentration & Valuation

Number of Stocks 22
Top 10 Stocks (%) 74.03
Top 5 Stocks (%) 44.98
Top 3 Sectors (%) 94.12
Portfolio P/B Ratio 4.48
Portfolio P/E Ratio 32.68

Portfolio Aggregates

Fund Category
Average Mkt Cap (Rs Cr) 46,844 52,129
Giant (%) 10.17 12.96
Large (%) 63.79 54.17
Mid (%) 14.53 25.62
Small (%) 11.51 8.70
Tiny (%) -- --

Value Research Fund Style

Sector Allocation vis-à-vis Category

ajax-loader
Please wait...

Top Holdings

Company Sector P/E 3Y High 3Y Low % Assets
up Dr. Reddy's Lab Healthcare 45.04 11.04 6.32 9.73
down Sun Pharmaceutical Industries Healthcare 55.23 12.32 7.94 9.57
equal Cipla Healthcare 32.21 11.10 5.81 8.70
down Aurobindo Pharma Healthcare 10.46 11.96 5.49 8.57
equal Divi's Laboratories Healthcare 56.09 11.18 7.74 8.41
down Lupin Healthcare 43.16 10.30 4.76 7.92
down Gland Pharma Healthcare 50.58 6.63 0.00 6.63
down Fortis Healthcare Healthcare -- 7.28 0.00 5.95
down Cadila Healthcare Healthcare 29.76 6.53 2.39 4.72
equal Thyrocare Technologies Healthcare 60.17 6.84 3.63 3.83
up Narayana Hrudayalaya Healthcare -- 4.09 1.04 3.35
up Apollo Hospitals Healthcare 229.48 4.41 0.00 2.98
up Abbott India Healthcare 50.79 7.97 2.23 2.74
up Jubilant Pharmova Healthcare 14.00 2.51 0.00 2.51
equal Indoco Remedies Healthcare 40.33 2.50 0.67 2.40
up Torrent Pharmaceuticals Healthcare 39.17 4.51 0.00 2.36
equal Sanofi India Healthcare 32.72 7.41 1.95 1.95
equal Jubilant Ingrevia Healthcare 228.09 0.84 0.00 0.84
new Pfizer Healthcare 49.69 0.67 0.00 0.49
equal Healthcare Global Enterprises Healthcare -- 1.35 0.26 0.41
equal Alkem Laboratories Healthcare 23.67 6.36 0.04 0.04
equal Biocon Healthcare 64.72 6.95 0.02 0.02

up down equal Indicates an increase or decrease or no change in holding since last portfolio
new Indicates a new holding since last portfolio

As on 31-May-2021

Fund Manager

— Sailesh Raj Bhan since 01-Jan-2013

Education: Mr. Bhan is an MBA (Finance) and CFA.

Experience: Prior to joining Nippon India Mutual Fund, he has worked with Emkay Share & Stock Broker Pvt. Ltd, Shah & Sequeira Invst. Pvt. Ltd, ICFAI- Securities Research Center Analyst - Equity Research.

Funds Managed:


-0.65%

Change from previous, NAV as on 18-Jun-2021

Growth: ₹ 314.7242

IDCW: ₹ 111.1244

Bonus: ₹ 314.7242


Investment Strategy

The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.

Investment Details

Minimum Investment (₹) 5,000
Minimum Addl Investment (₹) 1,000
Minimum SIP Investment (₹) 100
Minimum No of Cheques 60
Minimum Withdrawal (₹) 100
Minimum Balance (₹) 1
Lock-in Period Not Applicable
Exit Load 1% for redemption within 30 days

Basic Details

Fund House: Nippon India Mutual Fund
Launch Date: 01-Jan-2013
Return Since Launch: 19.46%
Benchmark: S&P BSE Healthcare TRI
Riskometer: Very High
Type: Open-ended
Assets: ₹ 5,238 Cr (As on 31-May-2021)
Expense: 0.80% (As on 30-Apr-2021)
Risk Grade: --
Return Grade: --
Turnover: 52.00%

Most Recent Dividends

Plan Record Date Dividend (₹ / Unit)  
IDCW26-Feb-20216.0000

 28-Feb-20203.9843
 05-Mar-20194.4270
 05-Mar-20186.0000
 06-Mar-20176.5000
 04-Mar-20167.0000
 30-Jan-20157.0000
 14-Feb-20144.5000

Contact Information

AMC: Nippon India Life Asset Management Ltd.

Address: Reliance Centre, 7th Floor, South Wing Off Western Express Highway Santacruz (East) Mumbai - 400055

Phone: 022-68334800 / 18602660111

Fax: 022-33037662

Email: [email protected]

Website: http://www.nipponindiamf.com

Registrar & Transfer Agent: KFin Technologies Pvt Ltd.

Address: 303, Vamsee Estates, Opp. Big Bazaar, Ameerpet, Hyderabad - 500016

Phone: 040-44857874

Email: [email protected]

Website: www.karvymfs.com

Last Session

Investors' Hangout

Your investment strategy after the debt fund fiasco

DateFriday, 18-Jun-2021
Time12:30 PM - 01:00 PM

Registration Over